Mind Medicine (MindMed) Inc. Q2 FY2025 earnings call

• Clinical Trials: Three pivotal Phase III trials for MM120 ODT in GAD (Voyage, Panorama) and MDD (Emerge) are ongoing with strong enrollment. MM120 ODT has breakthrough therapy designation from FDA, with Phase IIb results showing strong efficacy (e.g., 48% remission at week 12 in 100-microgram cohort).
• Treatment Model: Efficient single visit treatment model aligns with reimbursement pathways and supports full session coverage.
• Commercial Readiness: Building organization, making strategic hires, and market research shows 78% of interventional psychiatric providers believe psychedelic therapies will transform treatment landscape for GAD and MDD.
• Financials: Ended Q2 2025 with cash, cash equivalents, and investments totaling $237.9 million. R&D expenses $29.8M (up from $14.6M in 2024) due to MM120 ODT program; G&A expenses $11.1M (up from $9.8M in 2024) due to headcount growth.

No detailed segment performance with revenue contribution % as the transcript focuses on the MM120 ODT program and overall company performance rather than distinct product segments with financial breakdowns.

• Pivotal Phase III trials for MM120 ODT in GAD and MDD are on track with top line readouts anticipated in 2026.
• Confident in ability to deliver on mission of bringing differentiated best-in-class novel treatment option to patients with unmet mental health needs.

• Changes in market conditions.
• Difficulties associated with research, development, and regulatory approval processes for MM120 ODT and other programs.

Q: There's been a lot of data from other psychedelic companies. Thoughts on that relative to your programs?

A: Exciting time for the field. Our data from Phase II shows magnitude and durability of change not yet seen in other programs. Anticipate strong Phase III readouts in 2026.

Q: For Voyage and Panorama studies, powering assumptions and patient retention?

A: Powering assumptions assume 90% power to detect 5-point difference. Patient retention encouraged by open-label treatment opportunity in extension phase.

Q: Expectations for real-world use and commercialization of MM120 if Phase III data positive?

A: Extension phase of studies will generate real-world treatment patterns. Open-label treatment with threshold below enrollment threshold to understand real-world use.

Q: Enrollment trends for Voyage study and commercial preparatory work?

A: No exact enrollment numbers provided yet. Commercial preparatory work includes market access, targeting high-volume GAD facilities, and product positioning.

Q: Expectations for durability of efficacy beyond 12 weeks and dosing interval in real-world?

A: Efficacy beyond 12 weeks suggested by Phase II data. Dosing interval variable based on individual response patterns, not prespecified.

Q: Design of second Phase III MDD study?

A: Design not disclosed yet, but we've had progress with both GAD and MDD programs.

Q: Strategic collaborations and reimbursement?

A: Monitoring treatment dynamics and reimbursement engagement ongoing. Premature to discuss specific reimbursement details.

Q: Enrollment synergies between GAD and MDD trials and treatment visit guardrails?

A: Synergies exist with patients able to roll into MDD trial if diagnosed with MDD. Treatment visit has provider in room with monitoring to avoid psychotherapy.

Q: IP position and strategy, and FDA accelerated pathways?

A: Confident in IP strategy and patents. Breakthrough therapy designation offers avenues for acceleration.

Q: Financial resources and appropriateness given pivotal trials?

A: Efficiencies built into Phase III trials (e.g., using sites for multiple studies). Prudent growth with flexibility, having amended debt agreement for additional flexibility.